Genentech/Biogen Idec: Rituxan further expands its options

April 2006
PharmaWatch: Monthly Review;Apr2006, Vol. 5 Issue 4, p29
Market Research Report
The article reports that the U.S. Food and Drug Administration approved the drug Rituxan from Genentech Inc. and Biogen Idec Inc. to help treat rheumatoid arthritis (RA). The approval allows the companies to market Rituxan to be used with methotrexate for the treatment of signs and symptoms of RA, where the immune system inappropriately attacks joint tissue, causing inflammation and destroying cartilage, tendons and bones, often resulting in disability.


Related Articles

  • FDA approves tocilizumab to treat rheumatoid arthritis. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;2/15/2010, Vol. 67 Issue 4, p254 

    The article offers information on the U.S. Food and Drug Administration (FDA) approving the of tocilizumab drug. It reports that the drug treats rheumatoid arthritis and is marketed by Genentech Inc. which made the announcement on January 8. The company said that the drug is first monoclonal...

  • FDA: Complete Response for Rituxan in CLL.  // Bioworld Week;11/23/2009, Vol. 17 Issue 47, p5 

    The article reports on the status of biopharmaceutical firms Genetech Inc. and Biogen Idec Inc.'s drug application approval for Rituxan to treat chronic lymphocytic leukemia (CLL) in the U.S. It mentions that the Food and Drug Administration (FDA) has delayed its decision to approve the drug due...

  • Two New Approvals in Blockbuster Drug Arena. Mirasol, Feliza // Chemical Market Reporter;12/6/2004, Vol. 266 Issue 19, p16 

    This article reports that biotechnology companies Genentech Inc. and Biogen Idec Inc. are dosing the year with good news — early approvals of their two likely products, tarceva and tysabri, formerly referred to as antegren. Last month the U.S. Food and Drug Administration completed its...

  • Biotechs expand Rituxan potential. MIRASOL, FELIZA // Chemical Market Reporter;9/12/2005, Vol. 268 Issue 8, p36 

    Reports that biotechnology industries Biogen Idec and marketing partner Genentech Inc. plan to expand the potential of non-Hodgkin lymphoma therapy Rituxan by filing two supplemental biologies license applications with the United States Food and Drug Administration (FDA). Significance of the...

  • Genentech Reports 2nd Positive Study of ACTEMRA(r) Given by Subcutaneous Injection to Patients with Rheumatoid Arthritis.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article informs that Genentech Inc. has released the positive results from the clinical trial of ACTEMRA for the treatment of rheumatoid arthritis. It further informs that the company will be submitting the results to the U.S. Food and Drug Administration for gaining approval for ACTEMRA. It...

  • Genentech and Biogen Idec obtain FDA complete response for leukemia drug.  // PharmaWatch: Cancer;Jan2010, Vol. 9 Issue 1, p19 

    The article focuses on the complete response received by Genentech Inc. and Biogen Idec Inc. from the U.S. Food and Drug Administration (FDA), on their applications for chronic lymphocytic leukemia (CLL) drug. It reports that the companies had filed the applications on the use of chemotherapy...

  • Genentech/Biogen Idec: Rituxan further expands its options.  // PharmaWatch: Biotechnology;Apr2006, Vol. 5 Issue 4, p12 

    The article reports that the Rituxan drug developed by Genentech Inc. and Biogen Idec Inc. has gained another approval from the U.S. Food and Drugs Administration (FDA), making it the first selective B-cell therapy to be approved in rheumatoid arthritis in 2006. The FDA approval is for Rituxan...

  • FDA Approvals In March.  // BioWorld Insight;4/15/2013, Vol. 21 Issue 16, p7 

    A table is presented which lists several drugs approved by the U.S. Food and Drug Administration along with their companies including Biogen Idec Inc, Cangene Corp and Genentech Inc.

  • FDA Update.  // Pharmaceutical Representative;May2011, Vol. 41 Issue 5, p11 

    The article offers updates related to various drug approvals and actions by the U.S. Food and Drug Administration (FDA). The FDA has stated that it would not take action over compounding pharmacies which continue supplying 17 alpha hydroxyprogesterone caproate. The Merck & Co. Inc.'s...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics